Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | ACACA | Q13085 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcabene SCHEMBL4184554 | 1.00 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| Gemcabene SCHEMBL761631 | 0.98 | ACLY (0.55) | ACLYACACBACACAPPARATTR | |
| SCHEMBL14269711 | 0.96 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5524941 | 0.96 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5531453 | 0.96 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6258161 | 0.96 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5521484 | 0.94 | ACLY (0.57) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6267270 | 0.94 | ACLY (0.52) | ACLYACACBACACAPPARATTR | |
| SCHEMBL13210381 | 0.92 | ACLY (0.50) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5528996 | 0.91 | ACLY (0.52) | ACLYACACBACACAPPARATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715891-B2 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES | WARNER LAMBERT CO (US) | 2014-08-13 | — | — | EP | claimed |
| US-20100215654-A1 | Methods of treating Osteoarthritis with IL-6 Antagonists | PFIZER, INC. (US) | 2010-08-26 | — | — | US | claimed |
| EP-1715891-B1 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES | WARNER LAMBERT CO (US) | 2010-04-21 | — | — | EP | claimed |
| US-20080145367-A1 | Methods of Treating Osteoarthritis with Il-6 Antagonists | WARNER-LAMBERT COMPAY, LLC | 2008-06-19 | — | — | US | claimed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | claimed |
| EP-1715891-A2 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 OR ANTI-IL6 RECEPTOR ANTIBODIES | Warner-Lambert Company LLC (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005080429-A2 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 OR ANTI-IL6 RECEPTOR ANTIBODIES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050148654-A1 | Statin-carboxyalkylether combinations | BISGAIER CHARLES L (US) | 2005-07-07 | — | — | US | claimed |
| EP-1539127-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040072903-A1 | Carboxyalkylether-acat inhibitors combinations | AUERBACH BRUCE JEFFREY (US) | 2004-04-15 | — | — | US | claimed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | claimed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1292363-A2 | CARBOXYALKYLETHER-ACAT INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2003-03-19 | — | — | EP | claimed |
| WO-2001093845-A2 | CARBOXYALKYLETHER-ACAT INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2001-12-13 | — | — | WO | claimed |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NEUROBO PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS INC (US) | 2022-10-20 | — | — | US | disclosed |
| CN-111704543-A | Process and intermediates for preparing alpha, omega-dicarboxylic acid terminated dialkyl ethers | 燿石治疗公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004045596-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
| CN-1395555-A | Calcium dicarboxylate ethers, method of making same, and treatment of vascular disease and diabetes therewith | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NPC1L1, NOTUM, CEL | ACLY 2298/4885ACACB 1237/4885ACACA 1161/4885 |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | ACLY 3034/4885ACACB 2221/4885ACACA 1120/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | ACLY 560/4885ACACB 412/4885ACACA 228/4885 |
| US-20050148654-A1 | Statin-carboxyalkylether combinations | HMGCR, CETP, LCAT | ACLY 436/4885ACACB 29/4885ACACA 26/4885 |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NPC1L1, NOTUM, CEL | ACLY 2298/4885ACACB 1237/4885ACACA 1161/4885 |
| US-20040072903-A1 | Carboxyalkylether-acat inhibitors combinations | LCAT, CETP, ACAT2 | ACLY 98/4885ACACB 17/4885ACACA 5/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | ACLY 2661/4885ACACB 1828/4885ACACA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.